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Objectives: Neuropsychiatric symptoms are common in patients with Alzheimer disease
(AD). Treatment for both AD and psychiatric disturbances may affect the clinical ob-
served pattern and comorbidity. The authors aimed to identify whether particular
neuropsychiatric syndromes occur in untreated patients with AD, establish the severity of
syndromes, and investigate the relationship between specific neuropsychiatric syn-
dromes and AD disease severity. Design: Cross-sectional, multicenter, clinical study.
Participants: A total of 1,015 newly diagnosed, untreated outpatients with AD from five
Italian memory clinics were consecutively enrolled in the study from January 2003 to
December 2005. Measurements: All patients underwent thorough examination by
clinical neurologists/geriatricians, including neuropsychiatric symptom evaluation with
the Neuropsychiatric Inventory. Results: Factor analysis revealed five distinct neuropsy-
chiatric syndromes: the apathetic syndrome (as unique syndrome) was the most fre-
quent, followed by affective syndrome (anxiety and depression), psychomotor (agitation,
irritability, and aberrantmotor behavior), psychotic (delusions and hallucinations), and
manic (disinhibition and euphoria) syndromes. More than three quarters of patients
with AD presented with one or more of the syndromes (N 790, 77.8%), and more than
half exhibited clinically significant severity of symptoms (N  603, 59.4%). With the
exception of the affective one, all syndromes showed an increased occurrence with
increasing severity of dementia. Conclusions: The authors’ study supports the use of a
syndrome approach for neuropsychiatric evaluation in patients with AD. Individual
neuropsychiatric symptoms can be reclassified into five distinct psychiatric syndromes.
Clinicians should incorporate a thorough psychiatric and neurologic examination of
patients with AD and consider therapeutic strategies that focus on psychiatric syndromes,
rather than specific individual symptoms. (Am J Geriatr Psychiatry 2010; 18:1026–1035)
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The core symptom of Alzheimer disease (AD), themost common primary degenerative dementia,
is memory impairment, which is accompanied by
deficits in at least one other cognitive domain. How-
ever, both in AD and other primary degenerative
dementias, neuropsychiatric symptoms are com-
mon.1 Almost all patients with AD exhibit neuropsy-
chiatric symptoms at some point during the course of
the disease.2–4
Difficulties arise when characterizing neuropsy-
chiatric symptoms of patients with AD because they
are heterogeneous and unpredictable.5 These symp-
toms range from mood alterations (depression, anx-
iety, euphoria, and disinhibition) to psychotic mani-
festations (delusions and hallucinations), various
symptoms with motor manifestations (apathy, agita-
tion, wandering, and aggressiveness) and sleep or
appetite symptoms.2 Some authors have suggested
that this heterogeneity is due to neuropsychiatric
symptoms resulting from complex interactions of the
pathologic process with the premorbid specific per-
sonality and the environmental exposures or life ex-
periences of the patient.6,7
One approach to better understand the psychiatric
manifestations of AD is to evaluate whether specific
symptoms occur in association. Rather than viewing
individual symptoms separately, a limited number
of syndromes featuring associated symptoms are
identified. The potential advantages of this approach
are that neuropsychiatric syndromes might be less
heterogeneous and unpredictable and might be more
similar to primary psychiatric disorders, thus allow-
ing potentially fruitful analogies in terms of patho-
genesis, prognostic evaluation and treatment.8 How-
ever, studies have reported that the behavioral and
psychological syndromes associated with AD are not
completely consistent with the disorders seen in pa-
tients affected by primary psychiatric diseases.9–12
For example, although many studies report the exis-
tence of a psychotic syndrome characterized by the
concomitant occurrence of delusions and hallucina-
tions,13,14 these two specific psychotic symptoms are
also accompanied by symptoms of a different nature,
such as anxiety10 or agitation and irritability.11 Cur-
rent knowledge is limited by the fact that many
studies have been conducted on patients who are
undergoing treatment for either AD or neuropsychi-
atric problems, which can alter the pattern and se-
verity of psychiatric disturbances. Indeed, a Euro-
pean consortium study12 reported an influence of
acetyl cholinesterase inhibitors on apathy and psy-
chosis in AD, and it has been shown that donepezil
treatment reduces psychotic symptoms,15 and prazo-
sin reduces global neuropsychiatric symptom sever-
ity and frequency.16
The aim of this study was to identify neuropsychi-
atric syndromes in a large cross-sectional cohort of
newly diagnosed patients with AD, who were not
treated either for AD or neuropsychiatric phenomena.
Specifically, we aimed to: a) investigate whether spe-
cific neuropsychiatric syndromes can be characterized
in patients with AD, b) establish the occurrence and
severity of neuropsychiatric syndromes, and c) inves-
tigate the relationship between specific neuropsychiat-
ric syndromes and progression of the neurodegenera-
tive process, measured as the severity of dementia.
METHODS
Study Sample
Patients newly diagnosed as having probable AD,
who were consecutively seen in five Italian outpa-
tient memory clinics, were included in the study. The
diagnosis of AD was made according to National
Institute of Neurological and Communicative Dis-
eases and Stroke-Alzheimer’s Disease and Related
Disorders Association (NINCDS-ARDA)17 by trained
clinical neurologists and geriatricians. All patients were
free from treatment with either psychotropic drugs or
acetylcholinesterase inhibitors and had sufficient vision
and hearing abilities for compliance with testing pro-
cedures (eyeglasses and/or hearing aids permissible).
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We excluded patients who did not have a “reliable”
caregiver defined as a person who had contact with the
patient twice a week, including at least one personal
visit. Exclusion criteria were established through exam-
ination of the patient and review of medical records,
and interviews with the caregiver, and included i) ma-
jor medical illnesses, i.e., diabetes not stabilized, ob-
structive pulmonary disease or asthma, hematologic/
oncologic disorders, B12 or folate deficiency as
evidenced by blood concentrations below the lower
normal limit, pernicious anemia, clinically significant
and unstable active gastrointestinal, renal, hepatic, en-
docrine or cardiovascular system diseases, newly
treated hypothyroidism, liver function tests (alanine
transaminasi [ALT] aspartate aminotransferase [AST])
greater than three times the upper normal limit, creat-
inine concentrations150 mol/L; ii) presence of psy-
chiatric disorders with onset before AD (e.g., schizo-
phrenia and major depression); iii) presence of
neurologic disorders (e.g., stroke, Parkinson disease,
seizure disorder, and head injury with loss of con-
sciousness within the past year); iv) known or sus-
pected history of alcoholism or drug abuse; v) pa-
tients undergoing treatment with psychotropic drugs
or acetylcholinesterase inhibitors; vi) computed to-
mography or magnetic resonance imaging evidence
of focal brain parenchymal abnormalities; and vii)
nursing home patients or institutionalization within
last 3 months.
Based on the inclusion criteria, 1,015 subjects were
consecutively enrolled in the study from January 2003
to December 2005. The sociodemographic, clinical, cog-
nitive, functional, and behavioral characteristics are
summarized in Table 1. The study sample included
patients with AD with a mean Mini-Mental State Ex-
amination (MMSE)18 score of 18.3 at first diagnosis of
AD. This is similar to previous reports on the mean
scores for patients with AD at first diagnosis in clinical
settings.19,20 Less than one fifth of patients already had
severe dementia, despite the fact that we included only
patients with a new diagnosis of AD. This reflects the
clinical picture of dementia diagnoses today, because
there is a large variation in the time between the onset
of first symptoms and first physician consultation, with
TABLE 1. Total and Gender-Specific Demographic and Clinical Characteristics of the Study Sample
Men
(n  292)
Women
(n  723)
Total
(n  1,015)
Differences Between Men
and Women
n Percent n Percent n Percent 2 df p
Age at disease onset, years
65 219 75.0 616 85.2 835 82.3
65 73 25.0 107 14.8 180 17.7 14.835 1 0.000
Disease severity
Mild 137 46.9 246 34.0 383 37.7
Moderate 118 40.4 336 46.5 454 44.7
Severe 37 12.7 141 19.5 178 17.5 16.406 2 0.000
Mean SD Mean SD Mean SD t Test df p
Age, years (45–96) 73.3 0.5 75.1 0.3 74.6 0.2
Education, years (0–19) 7.6 0.2 5.7 0.1 6.2 0.1 3.499 1,013 0.000
Disease duration yrs (0–
24) 2.8 0.1 2.7 0.1 2.7 0.1 7.862 7.862 0.697
MMSE (0–30) 19.2 0.3 18.0 0.2 18.3 0.2 0.390 0.390 0.001
Instrumental ADL (0–8) 3.5 0.1 4.4 0.1 4.2 0.1 5.625 1,013 0.000
NPI items (0–12)
Delusions 1.0 0.1 1.2 0.1 1.1 0.1 1.131 1,013 0.258
Hallucinations 0.5 0.1 0.7 0.1 0.6 0.1 1.768 1,013 0.077
Agitation 1.5 0.1 1.7 0.1 1.6 0.1 0.869 1,013 0.385
Depression 2.2 0.2 2.8 0.1 2.7 0.1 3.263 1,013 0.001
Anxiety 1.6 0.1 2.3 0.1 2.1 0.1 3.695 1,013 0.000
Euphoria 0.3 0.1 0.4 0.0 0.4 0.0 1.899 1,013 0.058
Apathy 3.1 0.2 2.9 0.1 3.0 0.1 1.020 1,013 0.308
Disinhibition 0.7 0.1 0.6 0.1 0.6 0.1 0.081 1,013 0.936
Irritability 1.6 0.2 1.6 0.1 1.6 0.1 0.096 1,013 0.924
Aberrant motor
behavior 1.1 0.1 1.3 0.1 1.3 0.1 1.523 1,013 0.128
Total NPI score (0–81) 13.6 0.7 15.7 0.5 15.1 0.4 2.300 1,013 0.022
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some patients seeking medical care only when the dis-
ease is already at a severe stage.19,21–23
Cognitive, Functional, and Behavioral
Evaluations
The clinicians who made the AD diagnoses, as-
sessed all cognitive, functional, and behavioral char-
acteristics of the patients, including an interview
with next of kin and caregivers. Education was as-
sessed as the number of years of formal education.
Age at onset was defined as age at the onset of
cognitive symptoms severe enough to compromise
patient functioning and was assessed through an
interview with the caregiver.
Overall cognitive decline was assessed with the
MMSE.18 Instrumental activities of daily living
(IADL) were assessed with the IADL scale.24
Behavioral symptoms were measured with the Neu-
ropsychiatric Inventory (NPI)—10 items.25 The NPI is a
valid and reliable inventory assessing 10 neuropsychi-
atric dimensions in patients with dementia or other
neurologic disorders. The investigated dimensions/
symptoms are delusions, hallucinations, agitation, de-
pression, anxiety, euphoria, apathy, disinhibition, irri-
tability, and aberrant motor behavior. An informant
rates the frequency (0–3) and severity (0–4) of each of
these dimensions and the multiplication of the two
scores is used as final score, which ranges from 0 to 12
for each dimension, with a maximum total score of 120
in the 10-item version.
Ethical Considerations
The ethical committee of the participating centers
approved the protocol of the study. The nature and
purposes of this study were presented to the patients
and explained to their responsible caregivers and/or
legal guardians. Written informed consent was ob-
tained from patients or patients’ representatives and
caregivers before beginning the screening activities.
Statistical Analyses
First, baseline characteristics of the study sample
were calculated by gender, including disease sever-
ity, sociodemographics, cognitive and functional sta-
tus, and NPI performance. 2 and Student’s t tests
were used to assess differences between categorical
and continuous variables, respectively. Second, we
calculated the correlation index between MMSE and
NPI total score among all patients, with Pearson
correlation test. Third, to identify the principal com-
ponents of neuropsychiatric symptoms and examine
the syndrome associations of neuropsychiatric symp-
toms occurring together, we carried out a factor anal-
ysis on the 10 NPI symptoms within the total group
of patients with AD. The neuropsychiatric symptoms
were first analyzed with a principal component fac-
tor analysis with varimax rotation. This analysis was
performed to reduce the 10 NPI symptoms to a lim-
ited number of groups of symptoms (factors) occur-
ring in association. Each factor was defined by the
total variance explained, and by the symptoms that
were grouped together. A symptom entered on the
respective factor when the loading was 0.5 and
when its presence within the factor was logically
consistent. Following this, we categorized each pa-
tient on the basis of the presence of one or more of
the syndromes disclosed by the factor analysis. The
severity of the syndromes was calculated for each
patient as follows: “no syndrome” when patients
scored 0 on at least one of the symptoms in the
syndrome, “mild syndrome” when patients had NPI
score between 1 and 3 on every symptom in the
syndrome, and “clinically significant syndrome”
when patients scored 1 on all symptoms in the
syndrome with at least one symptom score 4.26
Patients were further divided according to the sever-
ity of the dementia measured by the MMSE score: mild
AD (MMSE18), moderate AD (MMSE 11–17), and
severe AD (MMSE 10). The proportion of patients
with clinically significant neuropsychiatric syndromes
was then calculated according to dementia severity.
Finally, we performed logistic regression analyses to
calculate the odds of having a clinically significant syn-
drome according to i) disease severity, withmild AD as
the reference category and ii) IADL score. Odds ratios
(ORs) and 95% confidence intervals (CIs) were calcu-
lated with logistic regression models. For all analyses,
statistical significance was set at the 0.05 level.
RESULTS
Demographic and clinical characteristics of the pa-
tients are shown in Table 1. Women were more likely
Spalletta et al.
Am J Geriatr Psychiatry 18:11, November 2010 1029
to have a disease onset65 years and had higher age
and IADL score. Men were more likely to have mild
disease severity, higher age, education, and MMSE.
Women had a higher mean NPI score for depression,
anxiety, and total NPI score.
The correlation index between MMSE and NPI
total score was 0.185 (p  0.002); 3.4% of the vari-
ance in the NPI score was explained by MMSE
(squared correlation index  0.1852  0.034). Al-
though the correlation is statistically significant, this
result shows that 4% of the entire NPI variance is
explained by differences in global cognitive function-
ing. This suggests that at a group level, patients with
AD with more severe cognitive deficits also have
more severe neuropsychiatric symptoms, but that at
the individual level, the severity of symptoms is
poorly predicted by the severity of cognitive deficits.
Table 2 shows the results of the factor analysis of
10 NPI symptoms in 1,015 patients with AD. The
analysis revealed five principal components (factors)
among the 10 NPI symptoms. These five factors ex-
plained 76% of the variability observed in the 10
symptomatologic dimensions of NPI. The first factor
revealed a “psychomotor syndrome,” comprised of
agitation, irritability, and aberrant motor behavior.
The second factor was strictly and uniquely related
to delusions and hallucinations, clearly indicating
the existence of a “psychotic syndrome.” The third
component revealed an “affective syndrome” com-
prised of anxiety and depression. The fourth com-
ponent was characterized by euphoria and disin-
hibition, suggesting the existence of a “manic
syndrome.” Finally, the fifth factor was related
uniquely to apathy, revealing an “apathetic syn-
drome.” It is noteworthy that all the symptoms
contributed positively to the severity of only one of
the five factors, suggesting that each NPI symptom
is independently characteristic of only one of the
syndromes.
The severity of the syndromes was calculated for
each patient including 1) no, 2) mild, and 3) clinically
significant syndrome. Table 3 shows the occurrence
of syndromes and severity according to sex. Most
patients presented one or more of the five syndromes
(N  790, 77.8%), and the majority had syndromes
severe enough to be clinically significant (N  603,
59.4%). The apathetic syndrome was the most fre-
quent followed by affective (depression and anxi-
ety) and psychomotor (irritability, aberrant motor
behavior, and agitation) syndromes. The fourth
TABLE 2. Factor Analysis on the 10 Items of NPI. Five
Factors Explain 76.0% of Total Variance
Factor and Eigen values
1 2 3 4 5
Delusions 0.245 0.840 0.013 0.148 0.078
Hallucinations 0.064 0.897 0.072 0.090 0.038
Agitation 0.692 0.395 0.195 0.066 0.025
Depression 0.031 0.132 0.825 0.049 0.258
Anxiety 0.223 0.024 0.841 0.122 0.075
Euphoria 0.029 0.152 0.039 0.887 0.017
Apathy 0.072 0.019 0.151 0.078 0.931
Disinhibition 0.375 0.091 0.049 0.684 0.128
Irritability 0.840 0.111 0.149 0.057 0.017
Aberrant motor
behavior
0.613 0.088 0.104 0.338 0.403
TABLE 3. Occurrence and Severity of Psychiatric
Syndromes by Gender
Syndromea
Men
n (%)
Women
N (%)
Total
n (%) p
Any syndrome
No 69 (23.6) 156 (21.6) 225 (22.2)
Mild 60 (20.5) 127 (17.6) 187 (18.4)
Clinically significant 163 (55.8) 440 (60.9) 603 (59.4) 0.319b
Psychotic
No 262 (89.7) 632 (87.4) 894 (88.1)
Mild 8 (2.7) 24 (3.3) 32 (3.2)
Clinically significant 22 (7.5) 67 (9.3) 89 (8.8) 0.589c
Affective
No 186 (63.7) 399 (55.2) 585 (57.6)
Mild 39 (13.4) 94 (13.0) 133 (13.1)
Clinically significant 67 (22.9) 230 (31.8) 297 (29.3) 0.016d
Manic
No 279 (95.5) 658 (91.0) 937 (92.3)
Mild 6 (2.1) 21 (2.9) 27 (2.7)
Clinically significant 7 (2.4) 44 (6.1) 51 (5.0) 0.036e
Psychomotor
No 255 (87.3) 620 (85.7) 875 (86.2)
Mild 3 (1) 21 (2.9) 24 (2.4)
Clinically significant 34 (11.6) 82 (11.3) 116 (11.4) 0.204f
Apathetic
No 105 (36.0) 287 (39.7) 392 (38.6)
Mild 78 (26.7) 157 (21.7) 235 (23.2)
Clinically significant 109 (37.3) 279 (38.6) 388 (38.2) 0.214g
aSyndrome severity: no syndrome, score  0 on at least one of the
symptoms in the syndrome; mild syndrome, NPI score 1–3 on every
symptom in the syndrome; clinically significant syndrome, NPI score
1 on all symptoms in the syndrome with at least one symptom
score 4.
b2 difference between men and women: 2 2.287, df  2.
c2 difference between men and women: 2 1.060, df  2.
d2 difference between men and women: 2  8.223, df  2
e2 difference between men and women: 2  6.660, df  2.
f2 difference between men and women: 2  3.176, df  2.
g2 difference between men and women: 2  3.082, df  2.
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most common syndrome was psychotic (delusions
and hallucinations) and finally the manic syn-
drome (euphoria and disinhibition).
Clinically significant syndromes occurred more
frequently than mild ones (Table 3). For example,
almost a third of patients had a clinically significant
affective syndrome (29.3%, N  297), whereas only
13.1% (N 133) presented with a mild severity of the
syndrome. This pattern occurred for all five syn-
dromes. Gender differences were observed only in
the affective and manic syndromes that were more
frequent in women.
Table 4 shows the occurrence of clinically signifi-
cant syndromes according to the severity of demen-
tia. All the syndromes with the exception of the
affective syndrome showed a clear increase of occur-
rence with increasing severity of the cognitive symp-
toms of dementia (Table 4). For example, patients
with moderate AD had a twofold odds of having the
psychomotor syndrome compared with patients
with mild AD, and the odds increased to 4.2 for
patients with severe AD. However, there was no
increased odds of having the affective syndrome in
patients with moderate AD or severe AD compared
with patients with mild AD. Similarly, lower IADL
performance was also associated with all of the syn-
dromes except the affective one (OR  1.0, 95% CI 
0.9–1.03, Wald 0.67, df 1, p 0.414). The odds of
having the psychotic syndrome increased by 40%
with each IADL point decrease (OR  1.4, 95% CI 
1.3–1.5, Wald  37.847, df  1, p  0.000), and a
similar patter was seen for manic (OR  1.2, 95%
CI  1.1–1.4, Wald  13.161, df  1, p  0.000),
psychomotor (OR  1.3, 95% CI  1.2–1.4, Wald 
32.457, df  1, p  0.000), and apathetic syndromes
(OR  1.2, 95% CI  1.1–1.2, Wald  30.541, df  1,
p  0.000).
DISCUSSION
The current study investigated the presence of neu-
ropsychiatric syndromes in patients with AD. We
identified distinct associations of NPI symptoms de-
picting five syndromes; the most common were an
apathetic and an affective syndrome. Syndromes
tended to occur at a clinically significant level. There
TABLE 4. Occurrence and Association Between Clinically Significant Syndromes and AD Severity
No/Mild
Syndrome n (%)
Clinically
Significant
Syndrome n (%)
Odds of Having a Clinically Significant
Syndrome
OR (95%
CI) Wald df
Psychotic
Mild AD 576 (94.4) 34 (5.6) 1.0 (reference)
Moderate AD 281 (87.0) 42 (13.0) 1.9 (1.1–3.2) 5.459 1
Severe AD 69 (84.1) 13 (15.9) 2.6 (1.4–4.8) 8.793 1
Affective
Mild AD 433 (71.0) 177 (29.0) 1.0 (reference)
Moderate AD 228 (70.6) 177 (29.0) 0.9 (0.7–1.2) 0.721 1
Severe AD 57 (69.5) 25 (30.5) 0.8 (0.5–1.2) 1.408 1
Manic
Mild AD 592 (97.0) 18 (3.0) 1.0 (reference)
Moderate AD 298 (92.3) 25 (7.7) 2.1 (1.0–4.4) 3.666 1
Severe AD 74 (90.2) 8 (9.8) 3.9 (1.8–8.8) 11.204 1
Psychomotor
Mild AD 563 (92.3) 47 (7.7) 1.0 (reference)
Moderate AD 276 (85.4) 47 (14.6) 2.0 (1.2–3.3) 7.059 1
Severe AD 60 (73.2) 22 (26.8) 4.2 (2.4–7.2) 26.620 1
Apathetic
Mild AD 396 (64.9) 214 (35.1) 1.0 (reference)
Moderate AD 197 (61.0) 126 (39.0) 1.2 (0.9–1.6) 1.367 1
Severe AD 34 (41.5) 48 (58.5) 1.7 (1.2–2.5) 8.596 1
Syndrome severity: no syndrome, score  0 on at least one of the symptoms in the syndrome; mild syndrome: NPI score 1–3 on
every symptom in the syndrome; clinically significant syndrome: NPI score 1 on all symptoms in the syndrome with at least one symptom
score 4.
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was an increased occurrence of all psychiatric syn-
dromes with increasing severity of AD, with the
exception of the affective syndrome. The patients
included in this study were newly diagnosed and
none of them were treated either for AD or for con-
trolling neuropsychiatric disturbances. Thus, the pat-
tern of neuropsychiatric symptoms in this cohort
represents the natural occurrence of these manifesta-
tions in persons with AD.
The analysis of principal components showed that
neuropsychiatric symptoms in persons with dementia
can be reduced to five groups of symptoms character-
izing five logically consistent syndromes. This group-
ing fitted well to our data and could explain 76% of
the total variance of symptom occurrence. Previous
studies8,9,11,12,27,28 identified a pattern of neuropsychi-
atric syndromes mainly in agreement with our find-
ings. The most notable difference of our study com-
pared with others9,27 was the distinct apathetic
syndrome. For example, the study of Hollingworth
et al. did not identify separate affective and apathetic
syndromes but instead reported a general “mood dis-
order” containing depression, apathy, and anxiety.
Proitsi et al. reported that apathy loaded both on a
“behavioral discontrol” factor and on a general “mood
disorder.” Apathy symptoms did not load high on the
“affective” component in our factor analysis but pre-
sented as an individual component. Furthermore, our
findings showed that patients with the affective and
apathetic syndrome had different characteristics;
women were more likely to have the affective syn-
drome, and the occurrence did not increase with AD
disease severity. This raises the question of why there is
this discrepancy concerning apathy between ours and
other studies? Our patients were free from pharmaco-
logic treatments, had a lower mean age at examination,
and had a much shorter mean disease duration than
many other studies, whichmay account for the discrep-
ancies of our findings.
Our results highlight that apathy is distinct from
other neuropsychiatric syndromes and support the
hypothesis that it might be a cognitive disturbance
related to cognitive decline in AD. Apathy is com-
posed of an affective, motor, and cognitive dimen-
sion. The cognitive component of apathy in AD
could be the most influential. As the cognitive de-
cline in AD worsened, there was an increasing oc-
currence of the apathetic syndrome in patients.
Further, it was extremely common, occurring in
more than half the patients with AD and more fre-
quently than all the other syndromes, even the affec-
tive one. This is in agreement with a previous report
that apathy is the most common neuropsychiatric
symptom in AD,29 which is unrelated to depression
in dementia patients.30 In addition, the fact that ap-
athy has often been found in conjunction with de-
pression and anxiety may be caused by the subtle
differences in apathy and depression that could be
misinterpreted.31 Our clinicians are experienced in
geriatric psychiatry, especially in the evaluation of
neuropsychiatric symptoms in AD, and they were
careful to accurately diagnose and distinguish de-
pressive and apathetic symptoms during interview
with patients and caregivers. If apathy is a cognitive
symptom in AD, then it could be linked with frontal
and executive dysfunction. Magnetic resonance im-
aging studies show an association between apathy
and medial frontal region structural abnormality in
AD,32 and there is neuropathologic evidence of in-
creased neurofibrillary tangles burden in the anterior
cingulate cortex of patients with AD with apathy.33
Apathy is highly associated with executive function-
ing, which is a cognitive domain dependent on the
frontal cortex. Together, these findings show that
apathy is the most frequent psychiatric symptom in
AD, which is related to the disease process and cog-
nitive decline.
The prevalence of syndromes was high; more than
three quarters of patients had at least one syndrome,
and almost 60% had one at a clinically significant
level. This is compatible with previous reports con-
cerning the prevalence of single behavioral symp-
toms in dementia.4,8 This suggests that the syndrome
approach does not reduce the sensitivity for identi-
fying behavioral manifestations in patients with AD.
The advantage of considering neuropsychiatric syn-
dromes instead of single symptoms is that the dis-
turbance can be regarded in a more coherent way,
particularly in view of specific treatments. The syn-
drome approach reduces the problems associated
with situations in which patients with AD have mild
symptoms that have uncertain clinical relevance.
Of the five syndromes, only the affective one did not
show an increased occurrence in the most severe forms
of cognitive impairment. It is known that depression
may be present in the early phases of AD.34 Less is
known about the other component, anxiety, although
research shows a high prevalence of anxiety in patients
Neuropsychiatric Syndromes in AD
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in the prodromal “MCI” phase of AD.35 It has been
suggested that neuropsychiatric symptoms represent
functional psychological responses to decreasing global
cognitive capacity.4 Although mood and memory, the
domains compromised both in affective disorders and
AD, share a common anatomic bases of the limbic
circuits, depression and anxiety may be epiphenomena
of the disease rather than direct consequences of neu-
rodegeneration, especially because we found no in-
crease in the occurrence of the affective syndrome with
increasing dementia severity.
Our finding that psychiatric syndromes in patients
with AD are consistent with primary psychiatric dis-
orders in AD supports the idea that the pathologic
process of AD causes cognitive and psychological
disturbances. Indeed, positron emission tomography
(PET) studies in apathy, depression, and psychoses
of patients with AD33,36,37 show a reduction of brain
metabolism localized in regions consistent with the
observed symptoms. Furthermore, we observed a
distinct syndrome of psychosis in our patients with
AD, characterized by delusions and hallucinations,
which supports previous research suggesting that psy-
chosis is a distinct clinical syndrome in AD,13,14 and
that patients with AD with hallucinations have distinct
neuropathologic and clinical characteristics.38
One limitation of our study is that principal com-
ponent analysis provides results that are best suited
to the data set on which it is conducted. Thus, the
syndromes we have identified might not be repre-
sentative of the pattern in other populations. For this
reason, our syndromes need to be verified in other
independent cohorts of patients. Furthermore, be-
cause we applied specific exclusion criteria for this
study, our results are applicable only to patients with
similar characteristics. It is also possible that there
may be a certain level of ascertainment bias in our
study because we used clinical data. Patients with
AD with neuropsychiatric symptoms might be more
likely to seek medical help than patients with AD
without such symptoms. Indeed, research has shown
that the time between onset of initial symptoms and
first consultation with a physician varies largely be-
tween patients, with a long delay to diagnosis in
some patients with AD.19,21–23 Furthermore, the
cross-sectional design of our study limits the inter-
pretation of the associations between disease severity
and neuropsychiatric symptoms, because these fac-
tors may also influence the decision to seek medical
help. Conversely, a major strength of our study is
that we examined a large cohort of patients with AD
who were not treated either for AD or neuropsychi-
atric disturbances, which may affect the natural his-
tory and pattern of behavioral symptoms.12,15,16 Be-
cause of the cross-sectional design of the study, we
were able to examine the occurrence of neuropsychi-
atric syndromes at the point of first diagnosis, with-
out the confounding effect of drug interventions.
Our study has relevant clinical and research impli-
cations. First, our findings support the use the syn-
drome approach for the clinical evaluation of neuro-
psychiatric symptoms in AD. Clinicians should
include a comprehensive psychiatric evaluation of
patients with AD, which focuses on the co-occur-
rence of behavioral symptoms and characterizes the
distinct syndromes when planning treatment and
care strategies. Second, our results have relevance to
public health planning. Behavioral disturbances in
AD are associated with institutionalization39 and
caregiver burden.40 Information on the prevalence
and pattern of neuropsychiatric syndromes can aid
public health planners to predict the care needs of
patients and their families. Finally, our findings help
to better understand disease mechanisms and
pathologic changes in AD that might be associated
with the different syndromes of neuropsychiatric
disturbances.
In conclusion, our study supports the use of the
syndrome approach for diagnosing neuropsychiatric
problems in patients with AD. Clinicians should incor-
porate a thorough psychiatric and neurologic examina-
tion of patients with AD and consider therapeutic strat-
egies that focus on psychiatric syndromes, rather than
specific individual symptoms. Finally, considering
the high prevalence and severity of neuropsychiatric
syndromes, long-term care plans and health care for
patients with AD should take into account the risk of
behavioral symptoms in addition to cognitive and
functional decline.
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